Uncategorized

NEW YORK and SOUTH SAN FRANCISCO, Calif., June 13, 2022 /PRNewswire/ — Biotech Acquisition Company (NASDAQ: BIOT) (“BAC”), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, and Blade Therapeutics, Inc. (“Blade”), a biopharmaceutical company based in South San Francisco, Calif., today announced that they have mutually agreed to terminate the previously announced Read more…

Extraordinary General Meeting of BAC’s shareholders postponed until June 3, 2022, at 10:00 a.m., Eastern Time NEW YORK and SOUTH SAN FRANCISCO, May 31, 2022 /PRNewswire/ — Biotech Acquisition Company (NASDAQ: BIOT) (“BAC“), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, and Blade Therapeutics, Inc. (“Blade”), a biopharmaceutical company based in South San Francisco, Read more…

Extraordinary General Meeting of BAC’s shareholders is scheduled for June 1, 2022, at 10:00 a.m., Eastern Time Post-closing company will be renamed “Blade Biotherapeutics, Inc.” upon Business Combination closing, with common stock and warrants expected to trade on the Nasdaq Global Market under ticker symbols “BBTX” and “BBTXW” Post-closing company has secured Read more…

NEW YORK, April 4, 2022 – Biotech Acquisition Company (NASDAQ: BIOT) (“BAC“), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, today announced that it has publicly filed, with the U.S. Securities and Exchange Commission, the first amendment to its registration statement on Form S-4, filed on March 15, 2022 (as Read more…

U.S. Food and Drug Administration (FDA) provides feedback necessary to proceed into a phase 2 proof of concept (PoC)/dose ranging study of cudetaxestat in patients with idiopathic pulmonary fibrosis (IPF) Company plans to advance cudetaxestat, a non-competitive inhibitor of autotaxin, into a 26-week phase 2 clinical trial in the second Read more…